Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month - Seite 2

The licensed technology was previously funded by both the National Institutes of Health/National Cancer Institute (NIH/NCI) and the Cancer Prevention and Research Institute of Texas (CPRIT).  There is an active $3.7 million award from NIH/NCI, which will financially support the continued clinical development of RNL for recurrent glioblastoma.

About Andrew Brenner, MD PhD

Dr. Brenner is a medical oncologist and tumor biologist with an interest in drug development for the management of primary brain tumors and breast neoplasms.  At the basic research level, his interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics.  This experience includes navigation of regulatory processes including IND enabling studies, authoring study protocols, coordinating multicenter studies, as well as acting as principal investigator of 14 industry and investigator initiated phase 1 trials since 2008.

A graduate of Texas A&M University, Dr. Brenner earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center - Science Park. Dr. Brenner received his medical degree from the Texas Tech University Health Science Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock, Texas.  He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.

About The Musella Foundation For Brain Tumor Research & Information

The Musella Foundation is a 501(c)(3) nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research.  Based in Hewlett, N.Y., the foundation was founded by Dr. Al Musella, DPM, a podiatrist in private practice in Hewlett.  The foundation has awarded over $4.7 million in direct patient assistance to help patients receive treatment.  More information may be found at www.virtualtrials.com.

About Plus Therapeutics, Inc.

Plus Therapeutics is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas.  The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT.